sapience logo
  • About
    • Overview
    • Management
    • Directors
    • Advisors
  • Approach
    • Overview
    • Spears™
    • PADS™
  • Pipeline
    • Overview
    • ST101
    • ST316
    • cJun Program
    • FoxP3 Program
  • Clinical Trials
    • ST101
    • Expanded Access
  • News & Events
    • Press Releases
    • Events
    • Publications
    • Presentations
    • Email Alerts
  • Careers
    • Careers
    • Open Opportunities
  • Contact

Press Releases

Press Releases

March 16, 2023

Sapience Therapeutics Announces Late-Breaking Research Poster Presentations on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023


March 14, 2023

Sapience Therapeutics Receives IND Clearance from FDA to Proceed with Phase 1-2 Study of ST316 in Patients with Solid Tumors


January 26, 2023

Sapience Therapeutics to Present at the Guggenheim Healthcare Talks 2023 Oncology Day


December 1, 2022

Sapience Therapeutics Announces Appointment of Abi Vainstein-Haras, M.D. as Chief Medical Officer


November 21, 2022

Sapience Therapeutics to Participate in Upcoming Investor Conferences


November 14, 2022

Sapience Therapeutics Announces Poster Presentation on ST101 Efficacy from Phase 2 Study in Recurrent Glioblastoma (GBM) at Society for Neuro-Oncology (SNO) Annual Meeting


November 10, 2022

Sapience Therapeutics Presents Data on the Immune Activating Function of ST101 at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting


October 13, 2022

Sapience Therapeutics Announces Poster Presentation on ST101 Efficacy, Long-Term Exposure and Safety in Phase 1-2 at 34th EORTC-NCI-AACR Symposium


October 12, 2022

Sapience Therapeutics Announces Poster Presentation on the Immune Activating Function of ST101 at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting


October 4, 2022

Sapience Therapeutics Awarded SBIR Phase 2 Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST101 in Breast Cancer


September 19, 2022

Sapience Therapeutics Announces Publication Showcasing the Mechanism of Action and Anti-tumor Activity of ST101, a Novel and Selective Peptide Antagonist of C/EBPβ, in Molecular Cancer Therapeutics


August 8, 2022

Sapience Therapeutics Announces Surgical Sub-Study of Ongoing Phase 1-2 Trial of ST101 in Recurrent and Newly Diagnosed GBM Patients


July 28, 2022

Sapience Therapeutics to Participate Virtually in Upcoming August Investor Conferences


June 3, 2022

Sapience Therapeutics Presents Phase 1 Data at ASCO 2022 Including Efficacy Proof-of-Concept with ST101 in Patients with Refractory Solid Tumors


June 2, 2022

Sapience Therapeutics Announces Expansion of Phase 2 Study Arm with ST101 in Patients with Recurrent Glioblastoma (GBM) Based on Confirmed Partial Response (PR)


May 31, 2022

Sapience Therapeutics Announces $41 Million Series B Financing to Advance Pipeline of Peptide Therapeutics Targeting Protein-Protein Interactions


May 12, 2022

Sapience Therapeutics Announces Poster Presentation on ST101 Phase 1 Study Results at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022


May 3, 2022

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST101 for the Treatment of Advanced Melanoma


April 11, 2022

Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug Well-Validated Cancer Pathways


March 31, 2022

Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs


March 15, 2022

Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect


March 9, 2022

Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022


February 15, 2022

Sapience Therapeutics Strengthens Executive Team with Appointments of Marisa Frackman as Chief Financial Officer and Seth I. Rubin as General Counsel


February 3, 2022

Sapience Therapeutics to Present at Guggenheim Healthcare Talks, 2022 Oncology Conference


January 6, 2022

Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101


December 15, 2021

Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma


December 9, 2021

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at the 2021 San Antonio Breast Cancer Symposium


December 6, 2021

Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for the Treatment of Recurrent Glioblastoma Multiforme (GBM)


December 1, 2021

Sapience Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Conference


November 10, 2021

Sapience Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference


October 29, 2021

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at 28th Prostate Cancer Foundation Annual Scientific Retreat and 18th International Congress of the Society for Melanoma Research


October 12, 2021

Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its β-catenin antagonist peptide (BCAP) Program


October 4, 2021

Sapience Therapeutics Announces Oral Presentation on ST101 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021


September 13, 2021

Sapience Therapeutics Announces Poster Presentation on ST101 at the European Society for Medical Oncology (ESMO) Congress 2021


July 29, 2021

Sapience Therapeutics Commences Dosing in Final Dose-Escalation Cohort of Ongoing Phase 1-2 Study of ST101


July 15, 2021

Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect


June 9, 2021

Sapience Therapeutics to Present at BIO Digital 2021


May 27, 2021

Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models


May 18, 2021

Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases


April 6, 2021

Sapience Therapeutics Announces Multiple Posters, Including Late-Breaker, at the American Association for Cancer Research (AACR) Annual Meeting 2021


March 4, 2021

Sapience Therapeutics to Present at the Upcoming 2021 Spring Private Company Showcase hosted by Credit Suisse, Solebury Trout, and Cooley


December 1, 2020

Sapience Therapeutics Appoints J. Andrew Sanford to Its Board of Directors


November 19, 2020

Sapience Therapeutics Renews Drug Discovery Pact with the University of Bath


November 17, 2020

Sapience Therapeutics Completes $14 million Preferred Stock Financing


August 19, 2020

Sapience Therapeutics Awarded SBIR Phase I Grant from National Cancer Institute


August 12, 2020

Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors


June 17, 2020

Sapience Therapeutics to Present Data on its Two Lead Programs at 2020 AACR Virtual Annual Meeting II


June 2, 2020

Sapience Therapeutics Announces FDA Acceptance of IND Application for ST101 in Advanced Cancer Indications


May 7, 2020

Sapience Therapeutics Receives United Kingdom Authorization to Initiate a Phase 1/2 Trial of Lead Candidate ST101 in Advanced Cancer Indications


January 7, 2020

Sapience Therapeutics to Present at Biotech Showcase 2020


October 29, 2019

Sapience Therapeutics to Present at the 2019 Life Sciences Summit


September 10, 2019

Sapience Therapeutics to Present at the 2019 BIO Investor Forum


September 4, 2019

Sapience Therapeutics Builds Clinical Team with Appointment of Alice Bexon, MD, as Chief Medical Officer


May 16, 2019

Sapience Therapeutics to Present at the 2019 BIO International Convention


March 14, 2019

Sapience Therapeutics to Present Poster on ST101 at the 2019 American Association for Cancer Research Annual Meeting


January 31, 2019

Sapience Therapeutics to Present at 2019 BIO CEO & Investor Conference


December 11, 2018

Sapience Therapeutics to Present at Biotech Showcase 2019


June 26, 2018

Sapience Therapeutics, Inc. Selected as a Winner of the JLABS NYC QuickFire Challenge


April 5, 2018

Sapience Therapeutics Enters into Drug Discovery Pact with the University of Bath


May 10, 2017

Sapience Therapeutics Adds Biotech Veteran, Christian S. Schade, to Board of Directors


March 29, 2017

Sapience Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ST-36 for the Treatment of Glioma


September 7, 2016

Sapience Therapeutics Adds Former Head of the National Cancer Institute, Samuel Broder, MD, to Board of Directors


July 20, 2016

Sapience Therapeutics, Inc. Enters Into Exclusive License Agreement With Columbia University for Novel Cancer Treatment


July 12, 2016

Sapience Therapeutics Completes $22.5 Million Series A Financing


March, 2023

Sapience Therapeutics Announces Late-Breaking Research Poster Presentations on ST101 and ST316 at the American Association for Cancer Research (AACR) Annual Meeting 2023


March, 2023

Sapience Therapeutics Receives IND Clearance from FDA to Proceed with Phase 1-2 Study of ST316 in Patients with Solid Tumors


January, 2023

Sapience Therapeutics to Present at the Guggenheim Healthcare Talks 2023 Oncology Day


December, 2022

Sapience Therapeutics Announces Appointment of Abi Vainstein-Haras, M.D. as Chief Medical Officer


November, 2022

Sapience Therapeutics to Participate in Upcoming Investor Conferences


November, 2022

Sapience Therapeutics Announces Poster Presentation on ST101 Efficacy from Phase 2 Study in Recurrent Glioblastoma (GBM) at Society for Neuro-Oncology (SNO) Annual Meeting


November, 2022

Sapience Therapeutics Presents Data on the Immune Activating Function of ST101 at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting


October, 2022

Sapience Therapeutics Announces Poster Presentation on ST101 Efficacy, Long-Term Exposure and Safety in Phase 1-2 at 34th EORTC-NCI-AACR Symposium


October, 2022

Sapience Therapeutics Announces Poster Presentation on the Immune Activating Function of ST101 at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting


October, 2022

Sapience Therapeutics Awarded SBIR Phase 2 Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST101 in Breast Cancer


September, 2022

Sapience Therapeutics Announces Publication Showcasing the Mechanism of Action and Anti-tumor Activity of ST101, a Novel and Selective Peptide Antagonist of C/EBPβ, in Molecular Cancer Therapeutics


August, 2022

Sapience Therapeutics Announces Surgical Sub-Study of Ongoing Phase 1-2 Trial of ST101 in Recurrent and Newly Diagnosed GBM Patients


July, 2022

Sapience Therapeutics to Participate Virtually in Upcoming August Investor Conferences


June, 2022

Sapience Therapeutics Presents Phase 1 Data at ASCO 2022 Including Efficacy Proof-of-Concept with ST101 in Patients with Refractory Solid Tumors


June, 2022

Sapience Therapeutics Announces Expansion of Phase 2 Study Arm with ST101 in Patients with Recurrent Glioblastoma (GBM) Based on Confirmed Partial Response (PR)


May, 2022

Sapience Therapeutics Announces $41 Million Series B Financing to Advance Pipeline of Peptide Therapeutics Targeting Protein-Protein Interactions


May, 2022

Sapience Therapeutics Announces Poster Presentation on ST101 Phase 1 Study Results at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022


May, 2022

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST101 for the Treatment of Advanced Melanoma


April, 2022

Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug Well-Validated Cancer Pathways


March, 2022

Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs


March, 2022

Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect


March, 2022

Sapience Therapeutics Announces Multiple Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022


February, 2022

Sapience Therapeutics Strengthens Executive Team with Appointments of Marisa Frackman as Chief Financial Officer and Seth I. Rubin as General Counsel


February, 2022

Sapience Therapeutics to Present at Guggenheim Healthcare Talks, 2022 Oncology Conference


January, 2022

Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101


December, 2021

Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for Advanced Cutaneous Melanoma


December, 2021

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at the 2021 San Antonio Breast Cancer Symposium


December, 2021

Sapience Therapeutics Receives FDA Fast Track Designation for ST101 for the Treatment of Recurrent Glioblastoma Multiforme (GBM)


December, 2021

Sapience Therapeutics to Present at the RBC Capital Markets Healthcare Private Company Conference


November, 2021

Sapience Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference


October, 2021

Sapience Therapeutics Announces Multiple Poster Presentations on ST101 at 28th Prostate Cancer Foundation Annual Scientific Retreat and 18th International Congress of the Society for Melanoma Research


October, 2021

Sapience Therapeutics Awarded SBIR Grant from National Cancer Institute (NCI) of the National Institutes of Health (NIH) for ST316, its β-catenin antagonist peptide (BCAP) Program


October, 2021

Sapience Therapeutics Announces Oral Presentation on ST101 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics 2021


September, 2021

Sapience Therapeutics Announces Poster Presentation on ST101 at the European Society for Medical Oncology (ESMO) Congress 2021


July, 2021

Sapience Therapeutics Commences Dosing in Final Dose-Escalation Cohort of Ongoing Phase 1-2 Study of ST101


July, 2021

Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect


June, 2021

Sapience Therapeutics to Present at BIO Digital 2021


May, 2021

Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models


May, 2021

Sapience Therapeutics Awarded SBIR Phase I Grant from National Institute of Allergy and Infectious Diseases


April, 2021

Sapience Therapeutics Announces Multiple Posters, Including Late-Breaker, at the American Association for Cancer Research (AACR) Annual Meeting 2021


March, 2021

Sapience Therapeutics to Present at the Upcoming 2021 Spring Private Company Showcase hosted by Credit Suisse, Solebury Trout, and Cooley


December, 2020

Sapience Therapeutics Appoints J. Andrew Sanford to Its Board of Directors


November, 2020

Sapience Therapeutics Renews Drug Discovery Pact with the University of Bath


November, 2020

Sapience Therapeutics Completes $14 million Preferred Stock Financing


August, 2020

Sapience Therapeutics Awarded SBIR Phase I Grant from National Cancer Institute


August, 2020

Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors


June, 2020

Sapience Therapeutics to Present Data on its Two Lead Programs at 2020 AACR Virtual Annual Meeting II


June, 2020

Sapience Therapeutics Announces FDA Acceptance of IND Application for ST101 in Advanced Cancer Indications


May, 2020

Sapience Therapeutics Receives United Kingdom Authorization to Initiate a Phase 1/2 Trial of Lead Candidate ST101 in Advanced Cancer Indications


January, 2020

Sapience Therapeutics to Present at Biotech Showcase 2020


October, 2019

Sapience Therapeutics to Present at the 2019 Life Sciences Summit


September, 2019

Sapience Therapeutics to Present at the 2019 BIO Investor Forum


September, 2019

Sapience Therapeutics Builds Clinical Team with Appointment of Alice Bexon, MD, as Chief Medical Officer


May, 2019

Sapience Therapeutics to Present at the 2019 BIO International Convention


March, 2019

Sapience Therapeutics to Present Poster on ST101 at the 2019 American Association for Cancer Research Annual Meeting


January, 2019

Sapience Therapeutics to Present at 2019 BIO CEO & Investor Conference


December, 2018

Sapience Therapeutics to Present at Biotech Showcase 2019


June, 2018

Sapience Therapeutics, Inc. Selected as a Winner of the JLABS NYC QuickFire Challenge


April, 2018

Sapience Therapeutics Enters into Drug Discovery Pact with the University of Bath


May, 2017

Sapience Therapeutics Adds Biotech Veteran, Christian S. Schade, to Board of Directors


March, 2017

Sapience Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ST-36 for the Treatment of Glioma


September, 2016

Sapience Therapeutics Adds Former Head of the National Cancer Institute, Samuel Broder, MD, to Board of Directors


July, 2016

Sapience Therapeutics, Inc. Enters Into Exclusive License Agreement With Columbia University for Novel Cancer Treatment


July, 2016

Sapience Therapeutics Completes $22.5 Million Series A Financing


sapeince logo

 ©2023 Sapience Therapeutics, Inc.
All Rights Reserved

Explore

  • About
  • Approach
  • Pipeline
  • Clinical Trials
  • News & Events
  • Careers
  • Contact

Contact

500 Mamaroneck Ave
Suite 320
Harrison, NY 10528

Tel: (914) 607-6930

Follow Us

linkedin logo

Legal

  • Policies
  • Disclaimer
logo
  • About
    • Overview
    • Management
    • Directors
    • Advisors
  • Approach
    • Overview
    • Spears™
    • PADS™
  • Pipeline
    • Overview
    • ST101
    • ST316
    • cJun Program
    • FoxP3 Program
  • Clinical Trials
    • ST101
    • Expanded Access
  • News & Events
    • Press Releases
    • Events
    • Publications
    • Presentations
    • Email Alerts
  • Careers
    • Careers
    • Open Opportunities
  • Contact